Cargando…
Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: Results of a cohort study
We determined whether rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) can predict remission or severe disability in rheumatoid arthritis (RA) patients treated with anti-tumor necrosis factor (TNF) alpha drugs. We performed a cohort study based on the clinical data from a...
Autores principales: | Santos-Moreno, Pedro, Sánchez, Guillermo, Castro, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380754/ https://www.ncbi.nlm.nih.gov/pubmed/30702571 http://dx.doi.org/10.1097/MD.0000000000014181 |
Ejemplares similares
-
Direct Comparative Effectiveness Among 3 Anti–Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis
por: Santos-Moreno, Pedro, et al.
Publicado: (2016) -
Nailfold Videocapillaroscopy in Patients with Rheumatoid Arthritis and Psoriatic Arthropathy on ANTI-TNF-ALPHA Therapy
por: Anghel, Daniela, et al.
Publicado: (2023) -
Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results
por: Süha, Çetin, et al.
Publicado: (2014) -
From the model of integral attention to the creation of centers of excellence in rheumatoid arthritis
por: Santos-Moreno, Pedro, et al.
Publicado: (2015) -
Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis
por: Benucci, M, et al.
Publicado: (2012)